Opportunity to Acquire the Intellectual Property of a Biopharmaceutical Company - Oxford Cannabinoid Technologies Holdings Plc - In Administration

Oxford Cannabinoid Technologies Holdings Plc - In Administration (June 2025)

The Intellectual Property of a Biopharmaceutical Company

Summary

OCTH operated as a biopharmaceutical company focused on developing new medicines targeting the endocannabinoid system. The Company’s primary assets include a proprietary and licensed intellectual property (IP) portfolio and clinical-stage drug development programmes. 

Website - www.oxcantech.com

Intellectual Property Portfolio

OCTH’s IP portfolio forms the foundation of its drug development strategy. The Company holds:

(a) A worldwide exclusive licence (excluding Japan) for a new chemical entity (NCE) from AskAt Inc.

(b) “Proprietarily Designed Inhaler”, designed for OCT’s specific 2^nd program. 

(c) Exclusive rights to 336 cannabinoid derivatives, licensed from Canopy Growth Corporation. These are a subset of a larger portfolio of 1,915 compounds covered by 14 patent families

Drug Developments Programmes

OCTH involved in developing multiple cannabinoid-based medicines, with two lead programmes:

 (a) Programme 1 – OCT461201 (CB2 Agonist for Neuropathic Pain)

  (i) OCTH’s lead clinical-stage programme, OCT461201, being developed to treat neuropathic pain. A Phase 1 (Single Ascending Dose) study has been completed, demonstrating positive safety data and no drug-related adverse effects.

(ii) The next step is a Multiple Ascending Dose (MAD) + Food Effect study, which is currently in planning. A Phase 2 trial will focus on neuropathic pain conditions, initially targeting Diabetic Peripheral Neuropathy (DPN).

(b) Programme 2 – OCT130401 (Inhaled Synthetic Phytocannabinoids via pMDI targeting Trigeminal Neuralgia (TN))

(i) This has a full pre-clinical data package and is ready to start a Phase 1.  The trial was to be conducted in Australia, where the regulatory process is faster than other jurisdictions and which benefits from favourable R&D incentives.

Expressions of Interest

Interested parties will be required to sign a nondisclosure agreement (NDA) before further information is provided.

Expressions of interest are required as soon as possible, please note any sale will be via an Administration process and likely to be on an accelerated timescale.

Please Download Notice of Sale for further information